Jintong Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jintong Hou has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Mary Ann Comunale
Department of Microbiology and Immunology/Department of Medicine/Department of Epidemiology & Biostatistics, Drexel University, Philadelphia, PA, United States
3 shared publications Bhavani Taramangalam
Drexel University/Tower Health Hospital, Philadelphia, USA
2 shared publications- Brian Wigdahl
Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
2 shared publications - Charles B. Cairns
Drexel University, Tower Health Hospital, Philadelphia, USA
2 shared publications - Elias El Haddad
Drexel University, Tower Health Hospital, Philadelphia, USA
2 shared publications - Florian Krammer
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
2 shared publications
Latest Publications
- Open Access
- 26 December 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 54, 101346
Sex differences in the association of vascular risk and APOE Genotype with cognitive decline and dementia: evidence from a U.S. longitudinal study
- 26 December 2025
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 54, 101346
Open AccessSex differences in the association of vascular risk and APOE Genotype with cognitive decline and dementia: evidence from a U.S. longitudinal study
- 11 September 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (3) , 231-240
Risk Factors for 15-Letter Visual Acuity Loss from Geographic Atrophy Progression over 1 Year in the Age-Related Eye Disease Study 2
- 11 September 2025
- Published by Elsevier in Ophthalmology Retina
- Vol. 10 (3) , 231-240
Risk Factors for 15-Letter Visual Acuity Loss from Geographic Atrophy Progression over 1 Year in the Age-Related Eye Disease Study 2
- 1 January 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (1) , e2469
Sample Size Estimation for Correlated Count Data With Changes in Dispersion
Clinical endpoints based on repeated measurements arise in many clinical research studies, and require specialized methods for sample size and power calculations. In clinical trials that measure counts over time, such as bleeding events in hemophilia, the dispersion of their distributions might change upon treatment and the measurements might be correlated. The generalized estimating equations (GEE) approach has been widely used for modeling correlated data and comparing rates. In this paper, we investigate the properties of GEE when applied to count outcomes with changes in dispersion. We derive general closed‐form formulas to estimate sample size when the dispersion parameters and distributions of count data vary across two correlated measurements based on the GEE approach. These formulas allow for power and sample size estimation for intra‐participant comparison of rates before and after an intervention, randomized controlled trials with equal allocation, or matched pairs designs. These formulas are derived for the following distributions: Poisson, negative binomial, zero‐inflated Poisson, and zero‐inflated negative binomial distributions, and do not assume that measurements before and after an intervention come from the same distribution. Furthermore, we propose modified methods for estimating sample size and confidence intervals for the negative binomial distributions to overcome Type I error inflation, which is especially useful for large changes in the negative binomial dispersion parameter. We perform simulations, and evaluate the performance of the empirical power and Type I error over a range of parameters. Applications and R functions implementing the methods are also provided.
- 1 January 2025
- Published by Wiley in Pharmaceutical Statistics
- Vol. 24 (1) , e2469
Sample Size Estimation for Correlated Count Data With Changes in Dispersion
Clinical endpoints based on repeated measurements arise in many clinical research studies, and require specialized methods for sample size and power calculations. In clinical trials that measure counts over time, such as bleeding events in hemophilia, the dispersion of their distributions might change upon treatment and the measurements might be correlated. The generalized estimating equations (GEE) approach has been widely used for modeling correlated data and comparing rates. In this paper, we investigate the properties of GEE when applied to count outcomes with changes in dispersion. We derive general closed‐form formulas to estimate sample size when the dispersion parameters and distributions of count data vary across two correlated measurements based on the GEE approach. These formulas allow for power and sample size estimation for intra‐participant comparison of rates before and after an intervention, randomized controlled trials with equal allocation, or matched pairs designs. These formulas are derived for the following distributions: Poisson, negative binomial, zero‐inflated Poisson, and zero‐inflated negative binomial distributions, and do not assume that measurements before and after an intervention come from the same distribution. Furthermore, we propose modified methods for estimating sample size and confidence intervals for the negative binomial distributions to overcome Type I error inflation, which is especially useful for large changes in the negative binomial dispersion parameter. We perform simulations, and evaluate the performance of the empirical power and Type I error over a range of parameters. Applications and R functions implementing the methods are also provided.
- 6 September 2024
- Published by Elsevier in Annals of Epidemiology
- Vol. 97, 93
Risk Prediction for Alzheimer’s Disease Mortality: Use XGBoost Survival Analysis
- 6 September 2024
- Published by Elsevier in Annals of Epidemiology
- Vol. 97, 93
Risk Prediction for Alzheimer’s Disease Mortality: Use XGBoost Survival Analysis
- Open Access
- 23 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104979
Host glycosylation of immunoglobulins impairs the immune response to acute Lyme disease
- 23 January 2024
- Published by Elsevier in EBioMedicine
- Vol. 100, 104979
Open AccessHost glycosylation of immunoglobulins impairs the immune response to acute Lyme disease
- Open Access
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- 9 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during human acute viral infection. The analysis of IgM N-glycosylation from healthy controls and hospitalized coronavirus disease 2019 (COVID-19) patients reveals increased high-mannose and sialylation that correlates with COVID-19 severity. These trends are confirmed within SARS-CoV-2-specific immunoglobulin N-glycan profiles. Moreover, the degree of total IgM mannosylation and sialylation correlate significantly with markers of disease severity. We link the changes of IgM N-glycosylation with the expression of Golgi glycosyltransferases. Lastly, we observe antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients and modulated by exoglycosidase digestion. Taken together, this work links the IgM N-glycosylation with COVID-19 severity and highlights the need to understand IgM glycosylation and downstream immune function during human disease.
- Open Access
- 2 June 2023
- Published by Springer Nature in Research Square
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human SARS-CoV-2, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during acute viral infection in humans. In vitro evidence suggests that the glycosylation of IgM inhibits T cell proliferation and alters complement activation rates. The analysis of IgM N-glycosylation from healthy controls and hospitalized COVID-19 patients reveals that mannosylation and sialyation levels associate with COVID-19 severity. Specifically, we find increased di- and tri-sialylated glycans and altered mannose glycans in total serum IgM in severe COVID-19 patients when compared to moderate COVID-19 patients. This is in direct contrast with the decrease of sialic acid found on the serum IgG from the same cohorts. Moreover, the degree of mannosylation and sialylation correlated significantly with markers of disease severity: D-dimer, BUN, creatinine, potassium, and early anti-COVID-19 amounts of IgG, IgA, and IgM. Further, IL-16 and IL-18 cytokines showed similar trends with the amount of mannose and sialic acid present on IgM, implicating these cytokines' potential to impact glycosyltransferase expression during IgM production. When examining PBMC mRNA transcripts, we observe a decrease in the expression of Golgi mannosidases that correlates with the overall reduction in mannose processing we detect in the IgM N-glycosylation profile. Importantly, we found that IgM contains alpha-2,3 linked sialic acids in addition to the previously reported alpha-2,6 linkage. We also report that antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients. Taken together, this work links the immunoglobulin M N-glycosylation with COVID-19 severity and highlights the need to understand the connection between IgM glycosylation and downstream immune function during human disease.
- 2 June 2023
- Published by Springer Nature in Research Square
Open AccessIgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition
The glycosylation of IgG plays a critical role during human SARS-CoV-2, activating immune cells and inducing cytokine production. However, the role of IgM N-glycosylation has not been studied during acute viral infection in humans. In vitro evidence suggests that the glycosylation of IgM inhibits T cell proliferation and alters complement activation rates. The analysis of IgM N-glycosylation from healthy controls and hospitalized COVID-19 patients reveals that mannosylation and sialyation levels associate with COVID-19 severity. Specifically, we find increased di- and tri-sialylated glycans and altered mannose glycans in total serum IgM in severe COVID-19 patients when compared to moderate COVID-19 patients. This is in direct contrast with the decrease of sialic acid found on the serum IgG from the same cohorts. Moreover, the degree of mannosylation and sialylation correlated significantly with markers of disease severity: D-dimer, BUN, creatinine, potassium, and early anti-COVID-19 amounts of IgG, IgA, and IgM. Further, IL-16 and IL-18 cytokines showed similar trends with the amount of mannose and sialic acid present on IgM, implicating these cytokines' potential to impact glycosyltransferase expression during IgM production. When examining PBMC mRNA transcripts, we observe a decrease in the expression of Golgi mannosidases that correlates with the overall reduction in mannose processing we detect in the IgM N-glycosylation profile. Importantly, we found that IgM contains alpha-2,3 linked sialic acids in addition to the previously reported alpha-2,6 linkage. We also report that antigen-specific IgM antibody-dependent complement deposition is elevated in severe COVID-19 patients. Taken together, this work links the immunoglobulin M N-glycosylation with COVID-19 severity and highlights the need to understand the connection between IgM glycosylation and downstream immune function during human disease.